🔴 Crispr Therapeutics is trading 4.2% down today as shares pull back on mixed valuation sentiment

Crispr Therapeutics is trading 4.2% down now at $56.72 as shares continue to pull back following recent CASGEVY label expansion headlines and mixed sentiment around valuation.

• The stock continues to decline despite recent bullish analyst commentary and an FDA label expansion for CASGEVY.
• Market movement suggests investors are reassessing risk and locking in prior gains rather than reacting to fresh company-specific news today.